Focused On-demand Library for Zinc finger SWIM domain-containing protein 7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q19AV6

UPID:

ZSWM7_HUMAN

Alternative names:

SWIM domain-containing and Srs2-interacting protein 1 homolog; SWIM-type zinc finger domain-containing protein 7

Alternative UPACC:

Q19AV6

Background:

Zinc finger SWIM domain-containing protein 7, also known as SWIM domain-containing and Srs2-interacting protein 1 homolog, plays a crucial role in the homologous recombination repair pathway of double-stranded DNA breaks. This process is vital during DNA replication or when DNA is damaged by external agents. The protein is essential for meiotic progression and, consequently, fertility, as evidenced by studies cited in PubMed.

Therapeutic significance:

Zinc finger SWIM domain-containing protein 7 is implicated in significant reproductive disorders, including Ovarian dysgenesis 10 and Spermatogenic failure 71. These conditions are characterized by primary amenorrhea and non-obstructive azoospermia, respectively, due to variants affecting the gene encoding this protein. Understanding its role could lead to novel therapeutic strategies for these fertility issues.